338 Index Name Paper ref. Name Paper ref. Hume, JR FC12.4.5 Humphrey, SJ Wed 048 Hung, C-F Tue 374 Hung, J-J Wed 368 Hunt, L Wed 190 Hunter, A Wed 096 Hurbin, F Mon 203 Hurd, YL FC14.1.2 Hurlé, MA Wed 087 Hurst, RS FC14.2.3 Hurt, C Wed 028 Hurttila, H Wed 448 Husbands, S YI.01 Husmann, K Thu 197 Hussain, M FC08.3.2 Husson, J-M W10.3 Hutchinson, D Thu 059, Wed 063, Mon 395 Huttunen, R Wed 444 Huynh, MB Mon 469 Hwa, L FC14.4.3 Hwang, L-L Wed 262 Hwang, M-S Tue 351 Iacob, M Wed 207 Iacono, A FC18.1.6 Iannazzo, S Wed 154, Mon 223 Iaquinto, G W02.3.3 Ibáñez, L Tue 087 Ibañez, MR Wed 169 Ibara, M A FC13.1.2 Ibarra, M Wed 049 Ibarra-Barajas, M Mon 168 Ibrahim, M Mon 372, FC01.2.5 Ichimura, A Wed 064 Ichishima, K Tue 162 Idriss Khodja, N Wed 273 Igarashi, T Tue 380, Wed 263 Igarashi, Y Mon 178 Igbe, I Wed 369 Ignatiev, I Tue 057 Iguegbe, A Wed 370 Iijima, H Tue 345, Mon 307 Iino, M PL11 Iizuka, K Thu 201, Mon 309 Ijzerman, AP FC11.2.3, FC11.2.5, FC11.4.6, W25.1 Ikarashi, N Mon 177, Mon 182 Ikeda, A Tue 156 Ikeda, R Tue 167 Ikeda, Y Mon 180 Ikeda-Matsuo, Y Mon 313 Ikegami, Y Mon 093 Ikehara, A Tue 060 Ikesue, H Mon 093 Ikuma, M Tue 473 Ikuta, Y Wed 413 Ilett, K FC10.5.3 Ilic, K FC10.2.6, Tue 367 Iljin, K Mon 410, Tue 436 Iljuhhina, J FC04.3.4 Imai, S Wed 065, Thu 188 Imaizumi, Y Wed 107, Thu 102, Thu 107 Imamoglu, S Mon 156 Imamura, Y Wed 247 Imanishi, M Wed 247 Imashova, S Tue 079 Immonen, E Mon 063 Imprialos, K Mon 367 Improta, G Tue 249 Imreh, A Mon 110, Mon 106 Inakuma, T FC16.4.6 Inal, A Tue 018 Inan, S Wed 038 Incerti, M Mon 381 Indarte, M Tue 059 Infanger, M Wed 252 Infante, F Tue 488, Mon 449 Ingelman-Sundberg, M FC13.5.1, W23.5, Tue 489 Ingham, TR Tue 136 Inotsume, N Tue 138, Tue 318 Inoue, H FC09.1.4, Mon 402 Inoue, Y Tue 060, Wed 414 Insel, P Thu 067 Institoris, A FC05.1.6 Inui, K Tue 225, Tue 156 Inui, N Thu 262, W23.1 Iordanidou, M Tue 224 Iosifidou, E Tue 246 Iqbal, MZ Thu 181 Iqbal, Z Tue 319 Irer, B Tue 200 Irie, M FC16.4.6 Irie, Y Wed 186, Tue 477 Irs, Alar FC01.2.1, FC04.3.4 Irving, H Thu 032 Isabel, O Mon 376 Isah, AO FC01.4.1, Tue 010 Isajevs, S Mon 429, Tue 253 Isaksson, A Wed 014, Wed 015 Isberg, V Wed 066 Ishibashi, N Tue 390 Ishida, S Wed 413 Ishiguro, H Thu 176 Ishiguro, S Wed 414 Ishihara, Y Tue 177, Tue 379 Ishihata, A Mon 178 Ishii, C Wed 422, Wed 415 Ishii, K Wed 264 Ishii, N Wed 422, Wed 415 Ishii-Nozawa, R Mon 179 Ishikawa, E Thu 268 Ishikawa, M Mon 025 Ishikawa, S FC16.4.6 Ishikawa, T Thu 226, Tue 136 Ishikawa, Y Tue 068, Thu 103 Ishimaru, Y Wed 067, Wed 075 Ishimura, M Tue 373 Ishizawa, K Mon 180 Ishizuka, T Tue 377 Ishola, I Wed 144 Isla, KKY Thu 355 Islam, T Tue 097 Ismail, M Tue 452 Ismail, R Mon 107 Ismail, Z Thu 328 Ismailoglu, S Wed 421 Ismailoglu, U Mon 314 Isnard, S Wed 208 Isotalo, T Thu 223
Name Paper ref. Name Paper ref. Israel, A Mon 295, Tue 127, Wed 212, Wed 265, Thu 205, Thu 254 Isrona, L Mon 475 Isuta, H Thu 220 Ito, F Tue 379 Ito, K Mon 177 Ito, S FC10.5.3, Mon 022, Mon 101 Ito, T Thu 331 Ito, Y Thu 038, Tue 216, Tue 217, Wed 371 Itoh, H Tue 132 Itoh, Y Thu 109 Itokawa, M Mon 173 Iuvone, T Tue 465, FC18.4.6 Ivankova-Susankova, K Thu 028 Ivanova, I Mon 479 Ivanova, S Thu 211 Ivashev, M Tue 176 Ivashev, MN Tue 179 Ivorra, MD Wed 068 Iwai, S Wed 372 Iwamoto, K Tue 266 Iwamoto, T Tue 071, Thu 286 Iwamoto, Y Wed 415, Wed 422 Iwanami, J Mon 439 Iwase, H Tue 167 Iwase, M Tue 320, Thu 319, Thu 343 Iwashita, M Wed 373 Iwata, F Thu 103 Iwata, N Wed 266, Thu 227 Iwata, R FC17.5.6 Izuhara, C Mon 405, Tue 467 Izumi, Y Mon 424, Mon 432, Mon 464 Izushi, Y Mon 329 Izzo, AA Wed 307 Jaako-Movits, K Thu 409 Jaba, I Mon 108, Tue 134 Jaberi, E Mon 454 Jackson, G FC08.1.3 Jacky, P Thu 037 Jacobs, GE FC17.3.5 Jacobs, M FC14.1.2 Jacobsen, S Thu 405 Jacobson, K Wed 108 Jacqz-Aigrain, E FC10.1.5, FC10.5.1, FC10.5.5, Wed 011 Jadhav, A Tue 124 Jaehde, U Mon 384 Jafari, M Tue 165 Jagtap, PN Thu 363 Jähnichen, S Thu 085 Jahnsen, JA Mon 397, Wed 069 Jahromy, MH FC17.2.6 Jaisin, Y Thu 305, Tue 277 Jakab, L Mon 283 Jäkälä, P W21.1, Wed 361 Jakobsen, S FC17.4.5, Tue 193, Thu 404 Jakobsson, P-J FC09.4.4 Jakovljevic, E FC10.2.6 Jakovljevic, M FC07.3.5 Jakovljevic, V Tue 148, Tue 454, Wed 321 Jalaei, J Tue 015 Jalali, A Tue 251 Jalil, ATMA Mon 001 Jalkanen, Aaro Mon 425 James, AE Tue 139 Jamnik, P Thu 329, Thu 318 Jamshidzadeh, A Mon 085, Mon 088 Jan, IU Tue 319 Janani, S Mon 131 Janchawee, B Wed 124 Jandric, D Tue 091, Tue 321, Tue 151 Janes, D Thu 359 Jang, C-G Mon 358, Tue 350, Mon 359, Mon 049, Mon 069, Tue 161, Tue 160, Mon 065, Tue 324, Tue 162, Wed 142, Tue 044, Tue 331, Tue 332, Tue 323, Tue 043, Tue 073, Tue 333, Mon 066, Wed 143 Jang, S Mon 033 Jang, SB Mon 013, Mon 226, Tue 349, Thu 418 Jang, YJ Tue 351 Jani, Nitya Mon 214 Janiszewski, M Wed 237 Janizewski, M Wed 233 Jankova, L W06.3 Jankovic, S FC07.3.5 Mon 039 Jankovic, SM Wed 435 Jankowski, J FC15.3.3 Jansakul, C Wed 374, Wed 375 Jansen, E Tue 242 Jansen-Olesen, I Wed 220, Thu 106 Mon 099 Jansone, B Mon 429, Tue 253 Janssen, BJA Thu 208, Wed 287, Thu 221 Janssen, G Thu 251 Janssens, K Wed 002 Jantaka, J Tue 007 Jantschak, F W13.4 Janzek, M Thu 359 Japundzic-Zigon, N Wed 435 Jara, P Tue 326 Mon 136 Jardine, D Mon 064 Jarrott, B FC03.1.6 Järvenpää, S-M Wed 445 Järvensivu, P Wed 446 Jasna, L Mon 347 Jauslin, P FC07.2.2 Javed, I Tue 319 Javid, FA Mon 246 Javidnia, K Wed 376 Javier, MCJ Wed 377 Javitch, JA FC02.1.2, FC02.3.5, Mon 058, Mon 073 Jayaprakash, V Tue 194 Jebabli, N FC07.3.6, Mon 020, Mon 021 Jebali, MA Mon 006 Jebrouni, N Tue 116, Thu 246 Jedlickova, B Tue 137 Jedlitschky, G FC02.4.2 Jennissen, K Tue 129 Jensen, B FC06.2.5, Wed 113 Jensen, BP Tue 322, Mon 064 Jensen, BP Mon 047 Jensen, GM FC02.2.5, Mon 071 Jensen, H FC06.2.5 Jensen, HB Wed 070 Index 339
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor